Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis
Authors:
- 8 November 2024
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (1) , 102018
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2022YFC3602000, 2022YFE0131700)
- Beijing Nova Program (20220484206)
- National Natural Science Foundation of China (82271835, 82071813)
This publication has 45 references indexed in Scilit:
- Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative ReviewDermatology and Therapy, 2024
- Large‐scale real‐world data analyses of cancer risks among patients with rheumatoid arthritisInternational Journal of Cancer, 2023
- Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic DrugsJAMA Network Open, 2023
- Tocilizumab in rheumatoid arthritis‐associated peripheral ulcerative keratitis: A 1‐year follow‐up case reportRheumatology & Autoimmunity, 2022
- Identification of lipopolysaccharide‐binding protein as a novel citrullinated autoantigen in rheumatoid arthritisRheumatology & Autoimmunity, 2022
- Rheumatology and functional genome analysis in East AsiaRheumatology & Autoimmunity, 2021
- Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk LesionsArthritis & Rheumatology, 2020
- Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid ArthritisRheumatology and Therapy, 2020
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006